Piper Jaffray Companies set a $20.00 price objective on Oxford Immunotec Global (NASDAQ:OXFD) in a research report report published on Wednesday morning, TipRanks reports. The firm currently has a buy rating on the stock.
A number of other brokerages have also recently commented on OXFD. ValuEngine cut shares of Oxford Immunotec Global from a hold rating to a sell rating in a research report on Wednesday, September 4th. TheStreet cut shares of Oxford Immunotec Global from a c- rating to a d+ rating in a research report on Monday, July 15th. BidaskClub upgraded shares of Oxford Immunotec Global from a strong sell rating to a sell rating in a research report on Friday. Finally, Zacks Investment Research cut shares of Oxford Immunotec Global from a buy rating to a hold rating in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and one has given a buy rating to the company. Oxford Immunotec Global currently has an average rating of Hold and a consensus price target of $19.00.
Shares of NASDAQ OXFD traded up $0.43 during mid-day trading on Wednesday, reaching $14.55. The company’s stock had a trading volume of 148,327 shares, compared to its average volume of 168,589. The stock has a 50-day moving average of $13.64 and a two-hundred day moving average of $14.84. The stock has a market capitalization of $378.31 million, a P/E ratio of 28.53 and a beta of 0.37. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.76 and a current ratio of 13.35. Oxford Immunotec Global has a 1-year low of $11.88 and a 1-year high of $19.19.
Oxford Immunotec Global (NASDAQ:OXFD) last issued its earnings results on Tuesday, August 6th. The company reported $0.02 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.07. The business had revenue of $19.60 million during the quarter, compared to analysts’ expectations of $19.32 million. Oxford Immunotec Global had a net margin of 208.48% and a return on equity of 14.76%. The company’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.25) earnings per share. Analysts predict that Oxford Immunotec Global will post -0.17 EPS for the current fiscal year.
In related news, CEO Peter Wrighton-Smith sold 10,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $13.86, for a total transaction of $138,600.00. Following the completion of the sale, the chief executive officer now directly owns 424,538 shares in the company, valued at $5,884,096.68. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $19.90, for a total transaction of $59,700.00. The disclosure for this sale can be found here. 4.21% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its position in Oxford Immunotec Global by 34.9% during the second quarter. Tower Research Capital LLC TRC now owns 2,734 shares of the company’s stock worth $37,000 after purchasing an additional 708 shares during the last quarter. Aperio Group LLC acquired a new stake in Oxford Immunotec Global during the second quarter worth about $42,000. JPMorgan Chase & Co. increased its position in Oxford Immunotec Global by 3.5% during the second quarter. JPMorgan Chase & Co. now owns 94,354 shares of the company’s stock worth $1,298,000 after purchasing an additional 3,157 shares during the last quarter. Campbell & CO Investment Adviser LLC increased its position in Oxford Immunotec Global by 15.0% during the second quarter. Campbell & CO Investment Adviser LLC now owns 24,941 shares of the company’s stock worth $343,000 after purchasing an additional 3,255 shares during the last quarter. Finally, Penn Capital Management Co. Inc. increased its position in Oxford Immunotec Global by 1.7% during the second quarter. Penn Capital Management Co. Inc. now owns 271,938 shares of the company’s stock worth $3,742,000 after purchasing an additional 4,648 shares during the last quarter. Hedge funds and other institutional investors own 94.09% of the company’s stock.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Read More: Futures Contract
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.